Rotavirus vaccines are being introduced in several low- and middle-income countries across the world with and without support from the GAVI Alliance. India has the highest disease burden of rotavirus based on morbidity and mortality estimates and several indigenous vaccine manufacturers are developing rotavirus vaccines. One candidate has undergone phase III testing and others have completed evaluation in phase II. Global data on licensed vaccine performance in terms of impact on disease, strain diversity, safety and cost-effectiveness has been reviewed to provide a framework for decision making in India. © 2014.
T.S., R., R., A., A., K., J.E., T., U., P., G., K., … N.C., G. (2014). Insights from global data for use of rotavirus vaccines in India. Vaccine, 32(S1), A171–A178. https://doi.org/http://dx.doi.org/10.1016/j.vaccine.2014.03.029